Mersana Therapeutics (Mersana Therapeutics) Interest Coverage : 0 (At Loss) (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Mersana Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Mersana Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-20.93 Mil. Mersana Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $-1.05 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Mersana Therapeutics's Interest Coverage or its related term are showing as below:

MRSN's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 122.085
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Mersana Therapeutics Interest Coverage Historical Data

The historical data trend for Mersana Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Mersana Therapeutics Interest Coverage Chart

Mersana Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

Get a 7-Day Free Trial

Mersana Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Coverage	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Mersana Therapeutics's Interest Coverage

For the Biotechnology subindustry, Mersana Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mersana Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Mersana Therapeutics's Interest Coverage falls into.

Mersana Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Mersana Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Mersana Therapeutics's Interest Expense was $-4.07 Mil. Its Operating Income was $-170.96 Mil. And its Long-Term Debt & Capital Lease Obligation was $28.30 Mil.

Mersana Therapeutics did not have earnings to cover the interest expense.

Mersana Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Mersana Therapeutics's Interest Expense was $-1.05 Mil. Its Operating Income was $-20.93 Mil. And its Long-Term Debt & Capital Lease Obligation was $28.30 Mil.

Mersana Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

Mersana Therapeutics (NAS:MRSN) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Mersana Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Mersana Therapeutics (Mersana Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (NAS:MRSN) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

0M4:Germany

Address

840 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.mersana.com

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Executives

Anna Protopapas	director, officer: President and CEO	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Mohan Bala	officer: SVP, Chief Development Officer	C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Tushar Misra	officer: Chief Manufacturing Officer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Brian Deschuytner	officer: Sr. VP, Finance & Product stgy	840 MEMORIAL DRIVE, CAMBRIDGE MA 01776
Ashish Mandelia	officer: VP, Controller	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Timothy B Lowinger	officer: Chief Scientific Officer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alejandra Carvajal	officer: Chief Legal Officer	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Arvin Yang	officer: Chief Medical Officer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Michael J. Kaufman	officer: Sr VP Chmistry, Man & Control	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Allene M. Diaz	director	C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Eva M. Jack	officer: CBO, Treasurer & Secretary	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Lawrence M Alleva	director	1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Scott D Sandell	10 percent owner